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A double-site enzyme-linked lactate dehydrogenase enzyme immunodetection assay was tested against field
isolates of Plasmodium falciparum for assessing in vitro drug susceptibilities to a wide range of antimalarial
drugs. Its sensitivity allowed the use of parasite densities as low as 200 parasites/l of blood. Being a
nonisotopic, colorimetric assay, it lies within the capabilities of a modest laboratory at the district level.
Multidrug resistance in Plasmodium falciparum remains one
of the leading problems facing effective malaria control in
tropical countries, particularly in Southeast Asia (1, 3, 5, 6).
Until the time when molecular markers can reliably be used to
determine levels of drug resistance in an area, heavy reliance
will remain on in vivo drug efficacy studies and in vitro assays
to determine drug susceptibilities in clinical isolates.
A double-site enzyme-linked lactate dehydrogenase enzyme
immunodetection (DELI) assay has recently been developed
(2) for assessing in vitro drug susceptibility that relies on the
detection of P. falciparum-specific lactate dehydrogenase. The
DELI method offers some unique advantages over the present
standard isotopic assay. Its sensitivity allows the measurement
of drug response with very low parasite densities (as low as
0.005% in one study [4]). In addition, since it is a nonisotopic,
enzyme-linked immunosorbent assay (ELISA), equipment is
simplified to the needs of running a straightforward ELISA.
To further evaluate the potential of the DELI microtest for
the monitoring of in vitro drug susceptibilities of field isolates,
we compared the DELI assay to the present standard isotopic
microtest for the susceptibilities first of the K1 laboratory
strain and then of 86 fresh clinical isolates to eight antimalarial
drugs (chloroquine, quinine, mefloquine, lumefantrine, artesu-
nate, dihydroartemisinin, atovaquone, and doxycycline).
Eighty-six fresh isolates for the assay comparison were ob-
tained between March 2001 and June 2002 from patients with
acute falciparum malaria attending the clinics of the Shoklo
Malaria Research Unit.
For the isotopic microtest (7), the fresh isolates were ad-
justed to an optimum density of 0.5 to 1.0% parasitized eryth-
rocytes and a hematocrit of 1.5% with freshly washed group O
erythrocytes and complete RPMI medium with 10% heat-in-
activated heterologous sera or commercial AB sera.
For the DELI microtest (2), the infected red blood cells
were diluted in culture medium at the same hematocrit (1.5%)
as that used for the isotopic microtest but at a parasitemia level
of 0.2% and were distributed in the same manner in the ap-
propriate antimalarial predosed plates. The plates were incu-
bated at 37°C in the presence of 5% CO2, 5% O2, and 90% N2
and were frozen after 42 h.
Concentration-response data were analyzed by a nonlinear
regression function to determine the 50% effective concentra-
tion (EC50), defined as the concentration of the drug which
inhibited 50% of (i) the uptake of [3H]hypoxanthine into the
nucleoprotein of the parasites (for the isotopic assay) or (ii)
the production of lactate dehydrogenase as determined by
optical density values from test wells compared to those ob-
tained from drug-free control wells (for the DELI method).
The effect of parasite density on EC50s was assessed in three
field isolates for chloroquine, quinine, mefloquine, and arte-
sunate. There was a nonsignificant trend for lower EC50s with
decreasing parasitemias (0.5 to 0.005% infected red blood
cells) for each drug and which proved almost significant for
chloroquine (r  0.55, P  0.053) and artesunate (r  0.53, P
 0.064). Where the parasite density was known and high
enough to necessitate dilution, optimal responses were consis-
tently obtained when the parasitemia level was adjusted to 0.1
to 0.2% (approximately 4,000 to 8,000 parasites/l of blood).
Table 1 shows a comparison of the EC50s for the K1 parasite
clone determined by the DELI and isotopic assays. The DELI
assay showed a greater variability than did the isotopic assay
and a nonsignificant trend to overestimate in vitro responses to
all drugs.
Eighty-six field isolates were assessed by both assay methods
for susceptibilities to eight antimalarial drugs (Table 2). Atova-
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quone and doxycycline provided the least reliable estimations
of EC50s. For atovaquone, 14 of 86 isolates (16%) produced a
poor dose response with the DELI assay compared with 9 of 86
(11%) for the isotopic assay (20.05, 2  15.1, P  0.001). For
doxycycline, only 2 of 86 isolates (2%) were unable to be
assessed by the DELI assay, compared to 29 of 86 isolates
(25%) by the isotopic assay (20.05, 2  20.5, P  0.001). These
differences suggest that the successful interpretation of dose
response with these two drugs is influenced by the assay used,
with the DELI assay proving the more reliable in the case of
doxycycline. Overall, geometric mean EC50s were significantly
higher by the DELI assay for chloroquine, lumefantrine, and
atovaquone but lower for artesunate and dihydroartemisinin.
No differences in mean EC50s were seen between the two
assays for quinine, mefloquine, and doxycycline. Differences
between the two methods became more apparent at higher
EC50s, particularly for artesunate, where levels were underes-
timated by the DELI assay (Fig. 1) (n  79, rs  0.732, P 
0.001) and atovaquone, showing a tendency to overestimate
responses (Fig. 2) (n  64, rs  0.793, P  0.001).
This study was prompted by a desire to have an assay that
could provide a relatively fast and accurate assessment of in
vitro drug susceptibility patterns of parasite populations and
that could be conducted in a modestly equipped laboratory at
the district level. This implied an assay that was sufficiently
sensitive to allow the use of virtually any fresh isolate without
regard to parasite density. We believe that the DELI assay
adequately fits these criteria and will prove a useful tool for
monitoring drug susceptibility patterns in areas where malaria
is endemic once the coated antibody plate and reagent kit
(ELISA-malaria antigen test; Diamed AG, 1785 Cressier
s/Morat, Switzerland) become commercially available.
TABLE 1. Comparative EC50s of eight drugs for the K1 parasite clone
Druga
DELI assay Isotopic assay
No. of
isolates
EC50 (ng/ml)
% CVc No. ofisolates
EC50 (ng/ml)
% CVc
Meanb 95% CId Range Meanb 95% CId Range
Chloroquine 6 218.5 170.4–280.2 173.1–340.3 26.8 6 188.1 180.2–196.4 175.0–192.3 4.4
Quinine 6 275.4 213.3–356.6 183.9–393.5 23.8 6 261.16 241.9–282.0 238.3–286.2 7.7
Mefloquine 6 13.7 8.7–21.5 7.6–19.7 36.5 6 14.79 12.5–17.4 11.7–17.8 13.8
Lumefantrine 6 5.3 4.0–7.0 3.3–6.8 23.1 6 5.15 4.6–5.8 4.3–5.8 10.1
Artesunate 6 1.02 0.95–1.44 0.95–1.65 21.5 6 0.982 0.79–1.22 0.74–1.23 19.6
Dihydroartemisinin 6 1.23 0.98–1.56 0.91–1.72 22.5 6 1.058 0.91–1.24 0.97–1.42 17.6
Atovaquone 4 3.22 0.98–10.10 3.2–5.6 53.5 6 3.82 3.13–4.67 2.93–4.88 17.5
Doxycycline 6 10,266 8,362–12,604 7,177–11,530 17.8 6 8,925 7,942–10,030 7,737–10,590 12.3
a For all drugs, there were no significant differences between the two methods (P  0.1, paired t test).
b Geometric mean 50% inhibitory concentration in vitro.
c CV, coefficient of variation.
d CI, confidence interval.
TABLE 2. Comparative EC50s of eight drugs for field isolates
Drug No. ofisolates
EC50 (ng/ml)
PDELI assay Isotopic assay
Meana 95% CIb Range Meana 95% CIb Range
Chloroquine 82 86.8 80.2–93.9 29.4–202.7 78.0 70.8–85.8 29.0–264.7 0.017
Quinine 81 229.8 202.1–261.3 42.7–731.8 208.7 181.1–240.7 31.0–1,336.7 NSd
Mefloquine 82 22.7 19.1–27.1 1.98–104.4 24.7 20.4–29.8 2.70–160.0 NS
Lumefantrine 75 26.0 22.4–30.2 3.64–126.8 21.6 18.4–25.4 4.20–106.6 0.008
Artesunate 79 0.61 0.54–0.69 0.08–1.44 0.96 0.84–0.92 0.28–4.43 0.000
DHAc 79 0.69 0.58–0.82 0.10–7.96 1.13 0.97–1.31 0.19–6.92 0.000
Atovaquone 64 2.39 1.9–3.0 0.31–27.7 1.75 1.4–2.1 0.34–11.5 0.047
Doxycycline 59 5,887 4,617–7,504 555–18,530 5,383 4,460–6,498 433–34,996 NS
a Geometric mean 50% inhibitory concentration in vitro.
b CI, confidence interval.
c DHA, dihydroartemisinin.
d NS, not significant.
VOL. 48, 2004 NOTES 1427
 o
n
 N
ovem
ber 4, 2015 by University of Queensland Library
http://aac.asm
.org/
D
ow
nloaded from
 
FIG. 1. Differences between responses to artesunate in vitro plotted against their means with 95% limits of agreement.
FIG. 2. Differences between responses to atovaquone in vitro plotted against their means with 95% limits of agreement.
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